Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

Nanoscope Therapeutics Inc. · NCT06805474

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
30
US sites recruiting
1
Study start
January 28, 2025
Record last updated
March 24, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying aid (eGlasses) and then with eGlasses. These results will be compared to ETDRS testing results for the same participants without eGlasses and then with eGlasses. Two cohorts will consist of participants who have vision loss due to STGD or geographic atrophy (GA) due to age-related macular degenerations (AMD). Normally sighted participants will provide a control group.

Being studied: Observational

Conditions: Macular Degeneration; Geographic Atrophy; Stargardt Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Males and females, age ≥ 18 years
  • Able to comprehend and give informed consent.
  • Able to comply with testing and all protocol tests.
  • Eligible for 1 of 3 cohorts listed below:

Cohort 1: Normal-Sighted Participants with clinically normal ocular findings and BCVA range 20/16 to \<20/40 in each eye (ETDRS letter score 71 - 90) Cohort 2: Moderately-Sight Impaired Participants with a BCVA range of 20/40 to \<20/200 (ETDRS letter score of 36 - 70) and a clinical diagnosis of STGD/GA Cohort 3: Severely-Sight Impaired Participants with a BCVA range of 20/200 to 20/800 (ETDRS letter score of 5 - 35) and a clinical diagnosis of advanced STGD/GA

  • Clinical diagnosis of STGD for cohorts 2 and 3
  • Clinical diagnosis for GA (due to AMD) for cohorts 2 and 3
  • Participants who have had anti-VEGF therapy 2 weeks prior to enrollment have to demonstrate 3 months of vision stability and be fluid free on OCT.

Exclusion Criteria

  • Concurrent participation in any interventional clinical trial or receipt of an investigational drug within the previous 6 months
  • Presence of any condition other than STGD or GA from AMD on slit lamp exam or dilated ophthalmoscopy that impairs visual acuity or visual fields e.g., corneal opacity, visually significant cataract or visual field loss in glaucoma
  • No intra-vitreal injection with anti-VEGF two weeks prior to the study
  • Presence of neurological condition that impairs visual acuity
  • Individuals who refuse or are incapable of performing the MLSDT of BCVA tests
  • Individuals with retinal prosthesis (such as ARGUS-II)

Recruiting US locations

  • Retina of North Texas,

    Dallas, TX 75243

    Site contact: Sai H Chavala, MD

Study contacts (from the official record)

  • Nozhat Choudry, Ph.D · (817) 857-1186 · nchoudry@nanostherapeutics.com
All diabetes studies in Texas →
A Prospective Observational Study to Assess the Reliability and… (NCT06805474) | Bored Studies